Showing results (151-160 of 182) with videos related to

Sort By:
Pageof 19
Journal of Neuro-Oncology|January 15, 2018
Neurologic complications of immune checkpoint inhibitorsAvi Fellner, Chen Makranz, Michal Lotem, et al.
International Journal of Clinical Oncology|November 20, 2014
A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001Deborah T Blumenthal, Cathryn Rankin, Keith J Stelzer, et al.
Cancer|June 4, 2008
External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trialDeborah T Blumenthal, Cathryn Rankin, Harmon J Eyre, et al.
Journal of Neuro-Oncology|August 18, 2016
Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patientsDeborah T Blumenthal, Addie Dvir, Alexander Lossos, et al.
Plos One|December 5, 2012
Hemodynamic response imaging: a potential tool for the assessment of angiogenesis in brain tumorsDafna Ben Bashat, Moran Artzi, Haim Ben Ami, et al.
AJNR. American Journal of Neuroradiology|July 9, 2016
Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade GliomasD Daniels, D Guez, D Last, et al.
International Journal of Radiation Oncology, Biology, Physics|November 6, 2017
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525Wenyin Shi, Molly Scannell Bryan, Mark R Gilbert, et al.
Nature|October 26, 2001
Complete genome sequence of Salmonella enterica serovar Typhimurium LT2M McClelland, K E Sanderson, J Spieth, et al.
Frontiers in Oncology|July 15, 2022
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and TemozolomideDaniela A Bota, Thomas H Taylor, Naomi Lomeli, et al.
Cancer|April 29, 2020
Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classificationRobert H Press, Sarah L Shafer, Renjian Jiang, et al.
Pageof 19